Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.date.accessioned | 2020-12-03T16:30:21Z | - |
dc.date.available | 2020-12-03T16:30:21Z | - |
dc.date.issued | 2020 | * |
dc.identifier.issn | 0748-7983 | * |
dc.identifier.other | OAK-28202 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/255588 | - |
dc.description.abstract | Background: This study was conducted to identify patients who may benefit from adjuvant chemoradiotherapy (CRT) for positive or close resection margin (RM) after curative resection of pancreatic adenocarcinoma. Methods: From 2004 to 2015, total of 472 patients with pancreatic adenocarcinoma underwent curative resection. After excluding patients with RM > 2 mm or unknown, remaining 217 patients were retrospectively analyzed. Forty-six (21.2%) patients were treated with adjuvant chemotherapy alone (CTx; mainly gemcitabine-based), 142 (65.4%) with adjuvant CRT (mainly upfront), and 29 (13.4%) patients didn't receive any adjuvant therapy (noTx group). Results: Locoregional recurrence rate was significantly lower in the CRT group (43.7%) than in the CTx group (71.7%) or noTx group (65.5%) (p = 0.001). Significant survival benefits of CRT over CTx (HR 0.602, p = 0.020 for overall survival (OS); HR 0.599, p = 0.016 for time to any recurrence (TTR)) were demonstrated in multivariate analysis. CRT group had more 5-year survivors than other groups. In the subgroup analysis, such benefits of adjuvant CRT over CTx was observed only in patients with head tumor & vascular RM > 0.5 mm, but not in patients with body/tail tumor or vascular RM ≤ 0.5 mm. In the CRT group, radiation dose≥54 Gy was significantly associated with better TTR and OS. Conclusions: Adjuvant CRT could improve TTR and OS compared to adjuvant CTx alone in patients with close RM under 2 mm. Radiation dose escalation may be beneficial when feasible. Modern CRT regimen–based randomized evidence is needed for these high-risk patients. © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology | * |
dc.language | English | * |
dc.publisher | W.B. Saunders Ltd | * |
dc.subject | Adjuvant chemoradiotherapy | * |
dc.subject | Pancreatic cancer | * |
dc.subject | Radiation dose | * |
dc.subject | Resection margin | * |
dc.title | Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma | * |
dc.type | Article | * |
dc.relation.issue | 11 | * |
dc.relation.volume | 46 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 2122 | * |
dc.relation.lastpage | 2130 | * |
dc.relation.journaltitle | European Journal of Surgical Oncology | * |
dc.identifier.doi | 10.1016/j.ejso.2020.07.029 | * |
dc.identifier.wosid | WOS:000582238700018 | * |
dc.identifier.scopusid | 2-s2.0-85089174675 | * |
dc.author.google | Kim B.H. | * |
dc.author.google | Kim K. | * |
dc.author.google | Jang J.-Y. | * |
dc.author.google | Kwon W. | * |
dc.author.google | Kim H. | * |
dc.author.google | Lee K.-H. | * |
dc.author.google | Oh D.-Y. | * |
dc.author.google | Lee K.B. | * |
dc.author.google | Chie E.K. | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.date.modifydate | 20240222162403 | * |